Our Hoofing IT Champions:
HOOFING IT! 2026 Total Raised $31,515
2026 Campaign: Hoofing IT 2026 raised $31,515 for NET cancer research!
Thank you to all our donors!
Final Results
HOOFING IT! 2026:
Raised $31,515!
Thank you to all our donors!

About cnetsadmin

This author has not yet filled in any details.
So far cnetsadmin has created 73 blog entries.

ESMO 2016 NET News

Clinical benefit demonstrated with everolimus and pasireotide LAR alone or in combination in the first randomised, prospective study entirely dedicated to advanced lung and thymic carcinoids. In patients with advanced [...]

By |2018-05-07T18:28:12-04:00October 13th, 2016|Clinical Trial, News, Treatment News|Comments Off on ESMO 2016 NET News

2016 Maureen Coleman Award – We Need Your Submissions!

One way that CNETS Canada honours those individuals who have made an outstanding commitment and contribution to the NET cancer patient community is through our annual Maureen Coleman award. Maureen [...]

By |2018-05-07T18:28:12-04:00September 23rd, 2016|News|Comments Off on 2016 Maureen Coleman Award – We Need Your Submissions!

First Global Neuroendocrine Tumor Patient Survey Results

“Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs” – a collaborative effort between the International Neuroendocrine Cancer Alliance (INCA) and [...]

By |2018-05-07T18:28:13-04:00June 22nd, 2016|News|Comments Off on First Global Neuroendocrine Tumor Patient Survey Results

New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors Not yet [...]

By |2018-05-07T18:28:13-04:00June 5th, 2016|Clinical Trial|Comments Off on New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Patient Survey: pCODR Patient Advocacy Group Input on a Drug Review for Everolimus (Afinitor): Indication for Gastrointestinal and Lung Neuroendocrine Tumours

The Pan-Canadian Oncology Drug Review (pCODR) will be considering an application for the drug Everolimus (Afinitor) indicated for Gastrointestinal and Lung Neuroendocrine (NET) Tumours.  Everolimus is a cancer medicine that [...]

By |2018-05-07T18:28:13-04:00April 16th, 2016|Treatment News|Comments Off on Patient Survey: pCODR Patient Advocacy Group Input on a Drug Review for Everolimus (Afinitor): Indication for Gastrointestinal and Lung Neuroendocrine Tumours

PRRT clinical trial at CHU de Québec

We are pleased to announce that this week, we are officially launching our 177Lu-octreotate PRRT clinical trial at CHU de Québec, which is called: Personalized Peptide Receptor Radionuclide Therapy of [...]

By |2018-05-07T18:28:14-04:00April 12th, 2016|Treatment News|Comments Off on PRRT clinical trial at CHU de Québec
Go to Top